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Disease duration as an indicator of the efﬁcacy
of liraglutide in patients with type 2 diabetes
mellitus
We would like to comment on the recent
article of Usui et al1 and highlight ﬁnd-
ings of our study. Usui et al. showed that
the glucose-lowering effect of liraglutide
as add on therapy to insulin relies on the
remaining b-cell function in type 2 dia-
betes.1 Counterintuitively, this effect was
not dependent on disease duration. We
retrospectively analyzed data from our
cohort of type 2 diabetes patients
(n = 69) at Slingeland Hospital, Doet-
inchem, the Netherlands, who instanta-
neously switched from insulin to
liraglutide between 2010 and 2016. Inclu-
sion criteria for switch were body mass
index ≥35 kg/m2 and glycated hemoglo-
bin (HbA1c) >53 mmol/mol (>7.0%).
Response was deﬁned as a decrease in
HbA1c; non-responding necessitates dis-
continuing liraglutide due to insufﬁcient
glycemic control or side-effects. Effects
on weight and HbA1c were analyzed
with a mixed model, and response by a
multivariate Cox survival analysis.
The mean age of the patients was
62 years (standard deviation 7.9 years),
and 54% were men. The median disease
duration was 13 years (interquartile
range 25–75, range 6–17.7 years), and
the mean HbA1c was 68.8 mmol/mol
(8.4%) during insulin therapy at a med-
ian daily dose of 96 units (range 54–
129 units). At 3, 6, 12 and 24 months,
the response rates were 65, 63, 51 and
23% for the total cohort, and 84, 84, 76
and 41% for patients with disease dura-
tion <10 years (n = 25). Responders’
median weight reduction at 3, 6 and
12 months was 1 kg (range 0–4.5 kg),
3 kg (range 0–6.3 kg) and 5 kg (range
1–11 kg), respectively. Responders’ med-
ian HbA1c reduction at 3, 6 and
12 months was 4 mmol/mol (range 0–
12.2 mmol/mol), 8.5 mmol/mol (range
2–26.5 mmol/mol) and 7 mmol/mol
(range 1–18 mmol/mol), respectively,
2.5% (range 0–3%), 2.9% (range 2.3–
4.6%) and 2.8% (range 2.2–3.8%). Insufﬁ-
cient glycemic control was the main rea-
son for non-responding (89%).
Longitudinal analysis adjusted for age
and sex showed a signiﬁcant positive asso-
ciation of disease duration with HbA1c
(0.33, 95% conﬁdence interval 0.07–0.58).
Survival analysis, adjusted for age, sex and
body mass index, showed a signiﬁcant
association between disease duration and
non-responding to liraglutide, with a haz-
ard ratio of 2.39 (95% conﬁdence interval
1.20–4.76) when disease duration was
dichotomized in <10 years or ≥10 years
(Figure 1).
Intriguingly, the present results seem to
conﬂict with the ﬁnding of Usui et al. not
establishing a relationship between disease
duration and successful therapy of liraglu-
tide in combination with insulin. On the
contrary, our results ﬁt with their ﬁnding
that liraglutide is most effective in
patients with the highest remaining b-cell
function, as it is well known that b-cell
function declines with disease duration.
We conclude that instantaneously switch-
ing from insulin to liraglutide is an option
for severely obese patients with type 2
diabetes with a short disease duration.
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Figure 1 | Kaplan–Meyer curve response of liraglutide regarding disease duration of type 2
diabetes mellitus <10 years vs ≥10 years.
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